Announcing New Board Member: Dewey McLin, PhD

We’re thrilled to welcome Dr. Dewey McLin to the KCNT1 Epilepsy Foundation’s Board of Directors. With over 20 years of experience in rare epilepsy, Dr. McLin played a key role in launching Epidiolex — the first FDA-approved cannabinoid treatment for childhood epilepsy. His background in both startup and established pharma companies, plus recent work on DEE-focused treatments, brings invaluable insight to our mission.

As KCNT1 research gains momentum, Dr. McLin’s leadership will help guide our advocacy, partnerships, and push for faster treatments.